Free cash flow has deteriorated significantly, with quarterly outflows reaching $12.1 million in 2026Q1, highlighting the persistent burn rate required to fund ongoing clinical operations.
| Cash from Operations | -35.74M | -27.79M | -19.15M | -18.09M | -17.35M | -14.3M | -1.13M | -338.29K | 714.99K | -126.39K | -29.57K |
| Operating CF Margin % | - | - | - | -6942.43% | -14056.31% | -461.11% | -161.69% | -30.13% | 17.69% | -6.13% | -3.06% |
| Operating CF Growth % | -361.79% | -45.11% | -5.88% | -4.23% | -21.36% | -1165.95% | -233.84% | -147.31% | 665.69% | -327.39% | - |
| Net Income | -50.96M | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M | -2.85M | -5.72M | -2.15M | -436.07K | -628.74K |
| Depreciation & Amortization | 47.85K | 60.5K | 26.27K | 177.4K | 6.72K | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.74M | 15.31M | 8.14M | 500.15K | 458.15K | 1.53M | 573.7K | 1.44M | 642.23K | 300.66K | 310.09K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7.75M | 5.05M | 0 | 31.54K | 67K | 721.63K | 1.61M | 2.32M | 709.27K | 534.62K | 95.71K |
| Working Capital Changes | -1.32M | 55.92K | 204.93K | 234.76K | 171.18K | -1.76M | -464.64K | 1.63M | 1.52M | -32.76K | 193.36K |
| Change in Receivables | 0 | 0 | 0 | 39.88K | 70.26K | -110.14K | 0 | 472.94K | -292.16K | -113.9K | 94.45K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 1.3M | 0 | -54.9K | 950.65K | 0 | 0 |
| Change in Payables | -104.75K | 146.83K | 271.78K | -504.41K | 61.4K | -630.9K | -247.07K | 47.46K | 600.72K | -78.27K | 0 |
| Cash from Investing | -99.49M | 2.05M | -37M | 11.66M | -16.01M | 0 | 0 | 0 | 87.1K | 0 | 0 |
| Capital Expenditures | -452.02K | -452.02K | 0 | -14.24K | -243.25K | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | 5.47% | 197.06% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 243.25K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 452.02K | 0 | 0 | 0 | -243.25K | 0 | 0 | 0 | 87.1K | 0 | 0 |
| Cash from Financing | 111.36M | 108.46M | 103.48M | 8.41M | -204.77K | 41.09M | 15.06M | -22.81K | -439.19K | 131.02K | -23.77K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -248.91K | -42.53K | 272.8K | -22.81K | -26.31K | 0 | 0 |
| Equity Issued (Net) | 111.33M | 108.46M | 103.48M | 8.41M | 44.14K | 41.14M | 14.79M | 0 | 1.18M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 31.62K | 0 | 0 | 0 | 0 | 848 | 0 | 0 | -1.59M | 131.02K | -23.77K |
| Net Change in Cash | -23.87M | 82.73M | 47.33M | 1.98M | -33.56M | 26.8M | 13.94M | -361.1K | 362.89K | 4.63K | -53.34K |
| Free Cash Flow | -36.19M | -27.79M | -19.15M | -18.1M | -17.59M | -14.3M | -1.13M | -338.29K | 714.99K | -126.39K | -29.57K |
| FCF Margin % | - | - | - | -6947.9% | -14253.37% | -461.11% | -161.69% | -30.13% | 17.69% | -6.13% | -3.06% |
| FCF Growth % | -86.72% | -45.11% | -5.79% | -2.87% | -23.06% | -1165.95% | -233.84% | -147.31% | 665.69% | -327.39% | - |
| FCF per Share | -0.37 | -0.28 | -0.28 | -3.39 | -4.19 | -4.71 | -0.67 | -0.20 | 0.54 | -0.07 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.71x | 0.58x | 0.70x | 0.95x | 0.96x | 0.97x | 0.40x | 0.06x | -0.33x | 0.29x | 0.05x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial execution failure
As reported in financial statements, Inhibikase Therapeutics' operating cash flow has consistently trailed net losses, with the OCF/NI ratio fluctuating significantly and reaching 0.74 in 2026Q1, highlighting the persistent gap between accounting losses and the actual cash required to sustain the firm's clinical development activities.
The divergence between net income and operating cash flow suggests that non-cash items and working capital adjustments are masking the true intensity of the company's cash burn. Investors should monitor this ratio closely, as a declining trend in cash conversion efficiency may indicate that the company is increasingly reliant on external financing to bridge the gap between its research ambitions and operational reality.
Based on IKT's reported figures, the free cash flow trajectory has deteriorated, with quarterly outflows reaching $12.1 million in 2026Q1, a significant increase from the $3.4 million burn observed in 2023Q4, reflecting the escalating costs associated with advancing the company's RAMP platform through clinical trials.
The consistent negative free cash flow is an expected characteristic of a pre-revenue biotech firm, yet the acceleration in the burn rate warrants further investigation into the efficiency of current clinical trial spending. This trend suggests that the company's capital requirements are expanding rapidly, which may necessitate future dilutive events if clinical milestones are not achieved within the projected timeframe.
According to recent SEC filings, Inhibikase Therapeutics has utilized significant stock-based compensation, including a $7.9 million charge in 2024Q4, which effectively masks the true cash-based operational costs and complicates the assessment of the company's underlying burn rate during periods of intense clinical development and talent retention.
The reliance on equity-based incentives appears to be a strategic mechanism to preserve cash, yet it obscures the true economic cost of operations from a cash flow perspective. Analysts should adjust for these non-cash charges to better understand the actual cash runway, as the current reporting structure may lead to an underestimation of the firm's long-term funding requirements.
As evidenced by the company's financial statements, capital deployment is currently restricted to funding R&D and clinical operations, with no dividends or share repurchases, reflecting a prudent, survival-oriented strategy that prioritizes maintaining a cash runway over returning capital to shareholders during this high-risk development phase.
The absence of capital returns is appropriate for a clinical-stage entity, but the focus on preserving cash suggests that management is acutely aware of the volatility in biotech funding markets. Investors should monitor whether this conservative approach to capital allocation remains sustainable if clinical trial timelines are extended or if the company decides to pursue additional indications for its pipeline.
Quick answers to the most common questions about buying IKT stock.
Inhibikase Therapeutics, Inc. (IKT) generated $-27.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Inhibikase Therapeutics, Inc. (IKT) reported negative free cash flow of $27.8M in 2025, indicating capital requirements exceeded cash from operations.
Inhibikase Therapeutics, Inc. (IKT) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.